BioMarin consolidates staff at Amicus HQ after closing $4.8B deal for rare disease peer

Shortly after locking down its $4.8 billion deal for rare disease compatriot Amicus Therapeutics, BioMarin is consolidating the workforce tied to the acquired company’s headquarters in New Jersey

Nội dung đang được cập nhật.